Other new first-in-human trials involve CD74, where Gilead and Sutro tried and failed, and the emerging target MAT2A.

Meanwhile, recent updates hint at more issues in the group’s pipeline of bispecific MAbs.

Following its odronextamab knockback, Regeneron now faces a delay to linvoseltamab.

But ficerafusp is limited to HPV-negative disease, and petosemtamab’s safety looks better.

A complete response letter for Merck & Co and Daiichi’s patritumab deruxtecan might not be fatal, but it’s certainly embarrassing.

As BAY2927088 enters phase 3 its lung cancer use will no longer be limited to exon 20.

Tagrisso is a knockout on PFS, but only OS will show whether it should be given before patients progress.